Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial

Ramakrishnan, Sanjay; Jeffers, Helen; Langford-Wiley, B; Davies, Joanne; Thulborn, Samantha; Mahdi, Mahdi; A’Court, Christine; Binnian, Ian; Bright, Stephen; Cartwright, Simon; Glover, Victoria; Law, Alison; Fox, Robin; Jones, Adam; Davies, Christopher; Copping, David; EK Russell, Richard; Bafadhel, Mona

doi:10.1016/s2213-2600(23)00298-9

Public

Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial

Published in The Lancet Respiratory Medicine • Nov 2, 2023

Authors:

Sanjay Ramakrishnan

Helen Jeffers

B Langford-Wiley

Abstract

Background Systemic glucocorticoids are recommended for use in chronic obstructive pulmonary disease (COPD) exacerbations; however, there is increased harm associated with their use. We hypothesised that the use of eosinophil biomarker-directed oral prednisolone therapy at the time of an exacerbatio...

Subject

Medicine

Exacerbation

Prednisolone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!